國立虎尾科技大學 |

mTOR Inhibition for Cancer Therapy: Past, Present and Future

Record Type:	Language materials, printed : Monograph/item
Title/Author:	mTOR Inhibition for Cancer Therapy: Past, Present and Future/ edited by Monica Mita, Alain Mita, Eric K. Rowinsky.
other author:	Mita, Monica.
Description:	VI, 300 p. 16 illus., 13 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Oncology . -
Online resource:	https://doi.org/10.1007/978-2-8178-0492-7
ISBN:	9782817804927

mTOR Inhibition for Cancer Therapy: Past, Present and Future
mTOR Inhibition for Cancer Therapy: Past, Present and Future[electronic resource] /edited by Monica Mita, Alain Mita, Eric K. Rowinsky. - 1st ed. 2016. - VI, 300 p. 16 illus., 13 illus. in color.online resource.

Forward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.

ISBN: 9782817804927

Standard No.: 10.1007/978-2-8178-0492-7doiSubjects--Topical Terms:

1253469
Oncology .

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

mTOR Inhibition for Cancer Therapy: Past, Present and Future
LDR:03286nam a22003975i 4500 001 980616
003 DE-He213
005 20200706051109.0
007 cr nn 008mamaa
008 201211s2016 fr | s |||| 0|eng d
020 $a 9782817804927 $9 978-2-8178-0492-7
024 7 $a 10.1007/978-2-8178-0492-7 $2 doi
035 $a 978-2-8178-0492-7
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a mTOR Inhibition for Cancer Therapy: Past, Present and Future $h [electronic resource] / $c edited by Monica Mita, Alain Mita, Eric K. Rowinsky.
250 $a 1st ed. 2016.
264 1 $a Paris : $b Springer Paris : $b Imprint: Springer, $c 2016.
300 $a VI, 300 p. 16 illus., 13 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Forward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.
520 $a This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
650 0 $a Oncology . $3 1253469
650 0 $a Hematology. $3 645254
650 0 $a Molecular biology. $3 583443
650 1 4 $a Oncology. $3 593951
650 2 4 $a Molecular Medicine. $3 668353
700 1 $a Mita, Monica. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1102998
700 1 $a Mita, Alain. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1102999
700 1 $a Rowinsky, Eric K. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1103000
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9782817804910
776 0 8 $i Printed edition: $z 9782817804934
776 0 8 $i Printed edition: $z 9782817805573
856 4 0 $u https://doi.org/10.1007/978-2-8178-0492-7
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)